GRK2 and familial dilated cardiomyopathy: Clinically approved for the treatment of DCM, the GRK2 inhibitor paroxetine improves cardiac function in mouse models of the disease by restoring circulating Treg cell populations via targeting of the GRK2-PI3K-Akt pathway [58].